Stock Events

Stock Events

NRX Pharmaceuticals

€0

0

+€0+0% Today

Statistics

Day High

-

Day Low

-

52W High

-

52W Low

-

Volume

-

Avg. Volume

-

Mkt Cap

0

P/E Ratio

-

Dividend Yield

-

Dividend

-

Upcoming

Earnings

19MayExpected

Q4 2025

Next

-0.03

0.1

0.23

0.36

Expected EPS

0.3597468

Actual EPS

N/A

People Also Follow

This list is based on the watchlists of people on Stock Events who follow B1Q.MU. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.

Pfizer is a global pharmaceutical company that competes with NRX Pharmaceuticals in the development and marketing of medications for various therapeutic areas, including mental health.

Johnson & Johnson

Johnson & Johnson, through its pharmaceutical segment Janssen, competes in developing treatments for disorders that NRX Pharmaceuticals targets, including mental health and other areas.

Merck & Co. is involved in the research, development, and marketing of drugs that address conditions similar to those targeted by NRX Pharmaceuticals, making them a direct competitor.

Eli Lilly and Company competes with NRX Pharmaceuticals in the psychiatric and neurological drug market, particularly in areas like depression and bipolar disorder.

AbbVie competes in the neuroscience and mental health drug market, areas that are of interest to NRX Pharmaceuticals, with a strong portfolio in psychiatric drugs.

Bristol-Myers Squibb

Bristol Myers Squibb offers a range of products that compete in the therapeutic areas targeted by NRX Pharmaceuticals, including mental health treatments.

Novartis AG competes with NRX Pharmaceuticals through its extensive research and development in therapies for neurological and mental health conditions.

GlaxoSmithKline competes in the pharmaceutical market for mental health medications, a key area of focus for NRX Pharmaceuticals.

Teva- Pharmaceutical Industries

Teva Pharmaceutical Industries is a global competitor in generic and specialty medicines, including those for neurological and psychiatric conditions that NRX Pharmaceuticals also targets.

AstraZeneca is involved in the development of therapies for various diseases, including those in the neurological and psychiatric domain, making them a competitor to NRX Pharmaceuticals.

About

NRX Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. Its products include ZYESAMI, an investigational drug that has completed a Phase IIb/III clinical study for COVID-19 related respiratory failure; and NRX-100 and NRX-101 oral therapeutics for the treatment of bipolar depression in patients with acute suicidal behavior/ideation and sub-acute suicidal ideation and behavior. The company was founded in 2015 and is based in Wilmington, Delaware.

Show more...

CEO

Dr. Jonathan C. Javitt M.D., M.P.H.

Country

United States

ISIN

US6294442099

Listings

0 Comments

Share your thoughts

FAQ

What is NRX Pharmaceuticals stock ticker?▼

Depending on the exchange, the stock ticker may vary. For instance, on exchange NRX Pharmaceuticals stocks are traded under the ticker B1Q.MU.

When is the next NRX Pharmaceuticals earnings date?▼

NRX Pharmaceuticals is going to release the next earnings report on May 19, 2026.

What were NRX Pharmaceuticals earnings last quarter?▼

B1Q.MU earnings for the last quarter are -0.03 EUR per share, whereas the estimation was 0.01 EUR resulting in a -703.77% surprise. The estimated earnings for the next quarter are N/A EUR per share.

In which sector is NRX Pharmaceuticals located?▼

NRX Pharmaceuticals operates in the Health & Wellness sector.

When did NRX Pharmaceuticals complete a stock split?▼

NRX Pharmaceuticals has not had any recent stock splits.

Where is NRX Pharmaceuticals headquartered?▼

NRX Pharmaceuticals is headquartered in Wilmington, United States.